Current Concepts in the Evaluation and Management of Abnormal Parathyroid Hormone (PTH) Levels Shireen Fatemi, M.D. April, 2012.
|
|
- Sabina Simpson
- 6 years ago
- Views:
Transcription
1 Current Concepts in the Evaluation and Management of Abnormal Parathyroid Hormone (PTH) Levels Shireen Fatemi, M.D. April, 2012 Disclosures I have no financial relationships with commercial interests, but I do have 4 parathyroid glands. They are all working normally to the best of my knowledge.
2 Cultural & Linguistic Competency Cultural and linguistic competency will be addressed in this activity. Differences in prevalence, diagnosis, treatment in a diverse population; linguistic skills; pertinent cultural data, etc. Outline Overview of parathyroid hormone secretion and action Primary hyperparathyroidism (PHPT) Secondary hyperparathyroidism Overview of vitamin D: metabolism and deficiency PTH and chronic kidney disease (CKD) Medical and surgical management of hyperparathyroidism Clinical application approach to the patient who has an elevated parathyroid hormone
3 Outline Overview of parathyroid hormone secretion and action Primary hyperparathyroidism (PHPT) Secondary hyperparathyroidism Overview of vitamin D: metabolism and deficiency PTH and chronic kidney disease (CKD) Medical and surgical management of hyperparathyroidism Clinical application approach to the patient who has an elevated parathyroid hormone Parathyroid hormone secretion and action PTH release, synthesis and degradation is regulated by calcium. PTH and calcitriol (1,25 D) are the two major hormones regulating calcium and phosphate homeostasis in the body. PTH 1-84 is the active hormone. It binds to PTH receptors in the bone and kidney, but is present in many other tissues (breast, skin, heart, blood vessels and pancreas). PTH has a short half-life (2 to 4 minutes). It is degraded in the liver and kidney.
4 Actions of PTH Principal targets are bone and kidney Bone: Mobilizes calcium from skeletal stores by activating bone resorption Kidney: Reabsorption of filtered calcium ( sca) Excretion of phosphate ( spo4) Synthesis of 1,25 vitamin D ( s1,25d) Other actions? Intestine, liver, adipose tissue, cardiovascular and neuromuscular function
5 Relationship between PTH and calcium PTH Calcium Calcium sensing receptors
6 Abnormalities in PTH secretion I Mutations in the calcium receptor Results in inappropriate PTH release (as in familial hypocalciuric hypercalcemia or autosomal dominant hypocalcemia) Primary hyperparathyroidism Parathyroid adenoma or hyperplasia causes a shift to a higher set-point for calcium Secondary hyperparathyroidism Kidney failure causes PTH hyperplasia, resulting in increased secretion of PTH as well as a reduced expression of calcium sensing receptors resulting in a higher calcium level Lithium Causes a reduced sensitivity to PTH secretion, thus resulting in a higher serum calcium level; also decreases renal calcium excretion Abnormalities in PTH secretion II Calcimimetic drugs Bind to the calcium sensing receptor and inhibit PTH secretion (cinacalcet) Nonhypercalcemic Vitamin D analogs 1,25 D analogues have been developed to inhibit PTH synthesis and secretion while minimizing intestinal calcium absorption or bone resorption (example : paricalcitol) Ectopic PTH secretion Largely due to tumor production of PTH related protein
7 Outline Overview of parathyroid hormone secretion and action Primary hyperparathyroidism (PHPT) Secondary hyperparathyroidism Overview of vitamin D: metabolism and deficiency PTH and chronic kidney disease (CKD) Medical and surgical management of hyperparathyroidism Clinical application approach to the patient who has an elevated parathyroid hormone Primary Hyperparathyroidism (PHPT)* *Sporadic vs. multiple endocrine neoplasia
8 Primary Hyperparathyroidism (PHPT) Most common clinical presentation: asymptomatic hypercalcemia. F>M, peak incidence 4 th -6 th decade Frankly elevated PTH with hypercalcemia or inappropriately normal PTH given the patient s hypercalcemia =normocalcemic primary hyperparathyroidism If uncertain of diagnosis hour calcium excretion, 25 D or 1,25 D may help Localization studies (sestamibi scans) are not used to establish the diagnosis Use total corrected serum calcium when evaluating hypercalcemia (correction: for every 1 gm increase in albumin, decrease the calcium by 0.8) Outline Overview of parathyroid hormone secretion and action Primary hyperparathyroidism (PHPT) Secondary hyperparathyroidism Overview of vitamin D: metabolism and deficiency PTH and chronic kidney disease (CKD) Medical and surgical management of hyperparathyroidism Clinical application approach to the patient who has an elevated parathyroid hormone
9 Etiologies of Secondary Hyperparathyroidism* 1.Low 25 vitamin D/hypocalcemia 2. Calcium malabsorption (bariatric surgery, celiac disease, fat malabsorption) / decreased intake 3. Renal losses hypercalciuria, diuretics 4. CKD (and acute renal failure)-impaired 1,25D formation, hyperphosphatemia 5. Lithium use 6. Calciolytic agents-cause lowering of serum calcium *Paul Miller, 2012 Outline Overview of parathyroid hormone secretion and action Primary hyperparathyroidism (PHPT) Secondary hyperparathyroidism Overview of vitamin D: metabolism and deficiency PTH and chronic kidney disease (CKD) Medical and surgical management of hyperparathyroidism Clinical application approach to the patient who has an elevated parathyroid hormone
10 120 INFLUENCE OF 25-OH VIT D ON SERUM PTH LEVELS 100 Serum PTH pg/ml OH Vit D ng/ml J Endo Invest Epub 5/2011 VITAMIN D METABOLISM
11 INDICATIONS FOR 25(OH)D SCREENING FOR VITAMIN D DEFICIENCY I Rickets Osteomalacia Osteoporosis Chronic kidney disease Hepatic failure Malabsorption syndromes (bariatric surgery, cystic fibrosis, Crohn s disease, inflammatory bowel disease, radiation enteritis). Hyperparathyroidism Medications (antiseizure, glucocorticoids,aids, antifungals, cholestyramine) INDICATIONS FOR 25(OH)D SCREENING FOR VITAMIN D DEFICIENCY II African-Americans and Hispanics Pregnant and lactating women Older adults with a history of falls and/or fractures Obese individuals (BMI over 30 kg/m 2 ) Granuloma forming disorders (sarcoidosis, TB, histoplasmosis, coccidiomycosis,berylliosis). Some lymphomas
12 If you want to keep sun energy all winter long drink vitamin D fortified Schlitz beer. Schlitz Sunshine Vitamin D Beer Schlitz aware of the benefits of vitamin D and in the 1930 s markets its product accordingly FDA (not amused)- prohibits vitamin D addition to the beer in 1947 THERAPY OF VITAMIN D DEFICIENCY 50,000 iu per week x 12 weeks Recheck If low, repeat If adequate, then iu/day Vitamin D supplementation appears safe and may offer more benefit than bone health Should be considered in all individuals
13 VITAMIN D: What Should We Tell Our Patients Vitamin D effects most tissues in the body Required for normal bone metabolism and may reduce risk of osteoporosis Likely will not be of benefit in treatment of disease May help reduce the risk of certain diseases Unlikely to produce side effects, if taken in recommended dosages However, if a little is good, a lot is not better Outline Overview of parathyroid hormone secretion and action Primary hyperparathyroidism (PHPT) Secondary hyperparathyroidism Overview of vitamin D: metabolism and deficiency PTH and chronic kidney disease (CKD) Medical and surgical management of hyperparathyroidism Clinical application approach to the patient who has an elevated parathyroid hormone
14 Changes in mineral metabolism as a consequence of CKD* GFR Stage 1,25 D PO4 Calcium PTH 2 fold 4 fold 8 fold *Andress, Semin in Dialysis, 2005 Diagnosis of Osteoporosis in Populations with Known Reduced GFR 1. Stage 1-3 CKD (GFR <90-30 ml/min): diagnose with osteoporosis the same as patients without National Kidney Foundation (NKF) defined CKD as long as there are no other biochemical abnormalities suggesting CKD-metabolic bone disease. 2. Stage 4-5 CKD (GFR <30 ml/min): Cannot use WHO criteria and/or fragility fractures since all forms of severe renal osteodystrophy (histomorphometry defined) may have low T-scores or low trauma fractures. Need Nephrologist s input. Moe S, et al, 2009 Miller, PD Sem Dial 2008
15 Outline Overview of parathyroid hormone secretion and action Primary hyperparathyroidism (PHPT) Secondary hyperparathyroidism Overview of vitamin D: metabolism and deficiency PTH and chronic kidney disease (CKD) Medical and surgical management of hyperparathyroidism Clinical application approach to the patient who has an elevated parathyroid hormone Symptomatic HPT is an Indication for Parathyroid Surgery SYMPTOMS ARE: Nephrolithiasis Fractures Neuropsychiatric
16 Asymptomatic Patients: Indications for Parathyroid Surgery:* Serum Ca 1.0 mg/dl or more above the upper limit of normal (11.5 mg/dl or > in SCPMG lab) Creatinine clearance < 60 ml/min T-score < at hip, spine or forearm or a fragility fracture Age < 50 years * From the rd International Workshop. Excludes those who refuse or are unfit for surgery monitor annual Ca,cr and BMD. Medical Management of asymptomatic PHPT* Indicated for those with low bone mass and risk factors for fracture, or those with osteoporosis who refuse or are not candidates for surgery For medical therapy, bisphosphonates are first choice. HT (estradiol) also effective Calcimimetics may prove useful to lower PTH Ensure 25 vitamin D status is normalized *Those who refuse or are not surgical candidates
17 Outline Overview of parathyroid hormone secretion and action Primary hyperparathyroidism (PHPT) Secondary hyperparathyroidism Overview of vitamin D: metabolism and deficiency PTH and chronic kidney disease (CKD) Medical and surgical management of hyperparathyroidism Clinical application approach to the patient who has an elevated parathyroid hormone PTH >65: 1. calcium high/(+ 25D low)? HPTH 2. calcium normal/low and vitamin D low?give vitamin D
18 Bibliography 1. Potts, JT, Juppner, H. Parathyroid hormone: molecular biology and regulation. In: Bilezikian, JP, Raisz, LG, Rodan, GA (Eds), Principles of Bone Biology, Academic Press, New York p Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int. 2000; 58(1): Brown EM Lithium induces abnormal calcium-regulated PTH release in dispersed bovine parathyroid cells J Clin Endocrinol Metab. 1981;52(5): Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ, Marx SJ, Peacock M, Mosekilde L, Bouillon R, Lewiecki EM Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94(2): Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92(8): Szulc P, Delmas, PD. Biochemical markers of bone turnover in osteoporosis. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6th ed, Rosen, CJ, (Ed), American Society of Bone and Mineral Research, 2008; p Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7): Silverberg SJ, Bilezikian JP SO. Asymptomatic Primary Hyperparathyroidism. A Surgical Perspective. Surgery Clin North Am. 2004;84 (3): Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G, Oppo A, Miccoli P, Berti P, Bilezikian JP, Pinchera A, Marcocci C SO. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007;92(8):3114. Bibliography 10. Andress, D. Vitamin D Treatment in Chronic Kidney Disease. Seminars in Dialysis. 2005; 18 (4): Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: Miller PD. Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 2007; 20: Eastell R, Arnold A, Brandi ML, Influence OF 25-OH VIT D On Serum PTH Levels J Endo Invest Eastell R, Arnold A, Brandi ML, et. al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94(2): Nissen PH, Christensen SE, Heickendorff L, et.al. Molecular genetic analysis of the calcium sensing receptor gene in patients clinically suspected to have familial hypocalciuric hypercalcemia: phenotypic variation and mutation spectrum in a Danish population. J Clin Endocrinol Metab. 2007;92(11): Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341(17): Lowe H, McMahon DJ, Rubin MR, et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007;92: Sywak MS, Knowlton ST, Pasieka JL. Do the National Institutes of Health consensus guidelines for parathyroidectomy predict symptom severity and surgival outcome in patients with primary hyperparathyroidism? Surgery 2002; 132: 1013.
19 Bibliography 19. Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective randomized trial. J Clin Endocrinol Metab 2007; 92: Guo CY, Thomas WE, al-dehaimi AW, et al. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: Parker CR, Blackwell PJ, Fairbalm KJ, Hosking DJ, Alendronate in the treatment of primary hyperparathyroid related osteoporosis: a 2 year study. J Clin Endocrinol Metab 2002; 87: Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009; 94: Bilezikian JP. Primary hyperparathyroidism. When to observe and when to operate. Endocrinol Metab Clin North Am 2000; 29: Bilezikian JP, Khan A, Potts J. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. J Clin Endocrinol Metab 2009; 94:335. Thank You! QUESTIONS??
Hyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationApproach to a patient with hypercalcemia
Approach to a patient with hypercalcemia Ana-Maria Chindris, MD Division of Endocrinology Mayo Clinic Florida 2013 MFMER slide-1 Background Hypercalcemia is a problem frequently encountered in clinical
More informationPRIMARY HYPERPARATHYROIDISM
PRIMARY HYPERPARATHYROIDISM HYPERPARATHYROIDISM Inappropriate excess secretion of Parathyroid Hormone in Primary Hyperparathyroidism Appropriate Hypersecretion in Secondary Hyperparathyroidism PTH and
More informationHyperparathyroidism. When to Suspect, How to Diagnose, When and How to Intervene. Johanna A. Pallotta, MD, FACP, FACE
Hyperparathyroidism When to Suspect, How to Diagnose, When and How to Intervene Johanna A. Pallotta, MD, FACP, FACE Potential conflicts of interest: None Johanna A. Pallotta, MD Outline Definition of hyperparathyroidism
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationHypercalcemia may be detected incidentally. Practice CMAJ. Primary hyperparathyroidism. Primer. Key points. The case. What causes hypercalcemia?
CMAJ Practice Primer Primary hyperparathyroidism Hafsah Al-Azem HBSc, Aliya Khan MD The case A 17-year-old man presented at the clinic with thirst, lethargy and fatigue that had been ongoing for several
More informationDisclosure. Primary Hyperparathyroidism 4 th IW. Topic Outline. Calcium, Vitamin D, PTH Disorders. I have nothing to disclose related to this topic
Disclosure Calcium, Vitamin D, PTH Disorders Chienying Liu MD Associate Clinical Professor Division of Endocrinology & Metabolism UCSF I have nothing to disclose related to this topic Topic Outline Calcium/Vitamin
More informationPRIMARY HYPERPARATHYROIDISM PRIMARY HYPERPARATHYROIDISM. Hyperparathyroidism Etiology. Common Complex Insidious Chronic Global Only cure is surgery
ENDOCRINE DISORDER PRIMARY HYPERPARATHYROIDISM Roseann P. Velez, DNP, FNP Francis J. Velez, MD, FACS Common Complex Insidious Chronic Global Only cure is surgery HYPERPARATHYROIDISM PARATHRYOID GLANDS
More informationhypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause
hyperparathyroidism A 68-year-old woman with documented osteoporosis has blood tests showing elevated serum calcium and parathyroid hormone (PTH) levels: 11.2 mg/dl (8.8 10.1 mg/dl) and 88 pg/ml (10-60),
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationMEDICAL POLICY EFFECTIVE DATE: 08/21/14 REVISED DATE: 04/16/15, 06/16/16, 07/20/17 SUBJECT: SCREENING FOR VITAMIN D DEFICIENCY
MEDICAL POLICY SUBJECT: SCREENING FOR VITAMIN D DEFICIENCY A nonprofit independent licensee of the BlueCross BlueShield Association PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not
More informationHypercalcemia. Hypercalcemia: When to Worry, When to Treat! Mineral Metabolism : A Short Course
Hypercalcemia: When to Worry, When to Treat! Michael A. Levine has no financial relationships to disclose or Conflicts of Interest to resolve. Michael A. Levine, M.D. This presentation will not involve
More informationPrimary Hyperparathyroidism
Primary Hyperparathyroidism Copyright Copyright 2019 2019 American American Associa7on Associa7on of Clinical of Clinical Endocrinologists Endocrinologists 1 Primary Hyperparathyroidism In primary hyperparathyroidism
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationHellenic Endocrine Society position statement: Clinical management of Vitamin D Deficiency. Spyridon Karras MD, Phd Endocrinologist
Hellenic Endocrine Society position statement: Clinical management of Vitamin D Deficiency Spyridon Karras MD, Phd Endocrinologist Pregnancy We recommend a minimum intake of 600 international units of
More informationPotential conflicts of interest: None
Hyperparathyroidism When to Suspect, How to Diagnose, When and How to Intervene November 6, 2013 Johanna A. Pallotta, MD, FACP, FACE Potential conflicts of interest: None Johanna A. Pallotta, MD Outline
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More informationParathyroid Imaging. A Guide to Parathyroid Surgery
Parathyroid Imaging A Guide to Parathyroid Surgery Primary Hyperparathyroidism (PHPT) 3 rd most common endocrine disorder after diabetes and hyperthyroidism Prevalence in women 2% Often discovered in asymptomatic
More informationDisclosure. Topic Outline. Calcium, Vitamin D, PTH Disorders. PTH/Calcium-Normal Physiology. I have nothing to disclose
Disclosure Calcium, Vitamin D, PTH Disorders I have nothing to disclose Chienying Liu MD Associate Clinical Professor Division of Endocrinology & Metabolism UCSF Topic Outline Calcium/Vitamin D/PTH physiology
More informationAsymptomatic Primary Hyperparathyroidism
The new england journal of medicine clinical practice Asymptomatic Primary Hyperparathyroidism John P. Bilezikian, M.D., and Shonni J. Silverberg, M.D. This Journal feature begins with a case vignette
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationSince the advent of multichannel serum chemistry
ONLINE EXCLUSIVE Padmaja Sanapureddy, MD; Vishnu Vardhan Garla, MD; Mallikarjuna Reddy Pabbidi, DVM, PhD Department of Primary Care and Medicine, G.V. (Sonny) Montgomery VA Medical Center, Jackson, Miss
More informationSouthern Derbyshire Shared Care Pathology Guidelines. Primary Hyperparathyroidism
Southern Derbyshire Shared Care Pathology Guidelines Primary Hyperparathyroidism Please use this Guideline in Conjunction with the Hypercalcaemia Guideline Definition Driven by hyperfunction of one or
More informationPrimary Hyperparathyroidism
Primary Hyperparathyroidism Claudio Marcocci, M.D., and Filomena Cetani, M.D., Ph.D. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various
More informationWhen the level of calcium in the blood falls too low, the parathyroid glands secrete just enough PTH to restore the blood calcium level.
Hyperparathyroidism Primary hyperparathyroidism is a disorder of the parathyroid glands, also called parathyroids. Primary means this disorder originates in the parathyroids: One or more enlarged, overactive
More informationVitamin D Hormone Du Jour
Vitamin D Hormone Du Jour J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine UCSF Why Is Vitamin D Important? Musculo-skeletal effects Possible other effects Immunomodulatory
More informationOutline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010
Outline The Role of Vitamin D in CKD Priscilla How, Pharm.D., BCPS Assistant Professor National University of Singapore Principal Clinical Pharmacist National University Hospital (Pharmacy and Nephrology,
More informationHypercalcemia. Brian Rose, M.D. Bozeman Health June 6, 2018
Hypercalcemia Brian Rose, M.D. Bozeman Health June 6, 2018 Hypercalcemia Diagnosis PTH Mediated Primary Hyperparathyroidism Lithium Familial Hypocalciuric Hypercalcemia Non PTH mediated Malignancy Humoral
More informationCase 2: 30 yr-old woman with 7 yr history of recurrent kidney stones
Case 2: 30 yr-old woman with 7 yr history of recurrent kidney stones Giuliano Mariani Regional Center of Nuclear Medicine, University of Pisa Medical School, Pisa (Italy) 30 yr-old woman with 7 yr history
More informationVitamin D Deficiency. Micol Rothman, MD Assistant Professor of Medicine Clinical Director Metabolic Bone Program University of CO-Denver
Vitamin D Deficiency Micol Rothman, MD Assistant Professor of Medicine Clinical Director Metabolic Bone Program University of CO-Denver 50 yo woman referred for osteoporosis What is striking about her
More informationNormocalcemic Primary Hyperparathyroidism: A Comparison with the Hypercalcemic Form in a Tertiary Referral Population
Pierreux Jan, Bravenboer Bert. Normocalcemic Primary Hyperparathyroidism: A Horm Metab Res 2018; 00: 00 00 Normocalcemic Primary Hyperparathyroidism: A Comparison with the Hypercalcemic Form in a Tertiary
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationPrimary Hyperparathyroidism: A Tale of Two Cities Revisited New York and Shanghai
ORIGINAL ARTICLE Bone Research (2013) 2: 162-169. www.boneresearch.org Primary Hyperparathyroidism: A Tale of Two Cities Revisited New York and Shanghai Jian-min Liu 1, Natalie E. Cusano 2, Barbara C.
More informationOSTEOMALACIA UPDATE. Nothing to Disclose. Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco
OSTEOMALACIA UPDATE Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco Nothing to Disclose 1 Case History 59 YO WM referred for evaluation of diffuse
More informationElecsys bone marker panel. Optimal patient management starts in the laboratory
bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic
More informationUPDATES ON PRIMARY HYPERPARATHYROIDISM. Natalie E. Cusano, MD, MS Director, Bone Metabolism Program Lenox Hill Hospital New York, NY
UPDATES ON PRIMARY HYPERPARATHYROIDISM Natalie E. Cusano, MD, MS Director, Bone Metabolism Program Lenox Hill Hospital New York, NY Disclosures Speaker (Honorarium): Shire Off-label use of estrogen, raloxifene
More informationParathyroid Disease Scenarios for the Practicing Clinician. Vijaya Chockalingam MD Faculty Endocrinologist Banner University Medical Center- Phoenix
Parathyroid Disease Scenarios for the Practicing Clinician Vijaya Chockalingam MD Faculty Endocrinologist Banner University Medical Center- Phoenix Clinical Scenario-1 73 year man (BK) with hypercalcemia
More informationClinical Policy: Measurement of Serum 1,25-dihydroxyvitamin D
Clinical Policy: Reference Number: CP.MP.152 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description
More informationHYPERCALCEMIA. Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra hospital, Isfahan university of medical sciences
HYPERCALCEMIA Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra hospital, Isfahan university of medical sciences ESSENTIALS OF DIAGNOSIS Serum calcium level > 10.5 mg/dl Serum ionized
More informationCases in Endocrinology
Bones, Moans and Groans Diagnosing and Treating Primary Hyperparathyroidism By M. Usman Chaudhry, MD Table 1 Laboratory parameters Her bone density had osteopenic T-Scores of -2.3 at lumbar spine, and
More informationHyper and hypocalcaemia. Prof Tricia Tan
Hyper and hypocalcaemia Prof Tricia Tan Learning Objectives Basic physiology of Ca regulation Case presentations Take home messages Calcium Total body calcium content ~1300g 99% in bone 1% intracellular
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationCalcium metabolism and the Parathyroid Glands. Calcium, osteoclasts and osteoblasts-essential to understand the function of parathyroid glands
Calcium metabolism and the Parathyroid Glands Calcium, osteoclasts and osteoblasts-essential to understand the function of parathyroid glands Calcium is an essential element for contraction of voluntary/smooth
More informationBone Disorders in CKD
Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis
More informationPrimary hyperparathyroidism is mild disease worth treating?
CONFERENCE SUMMARIES Clinical Medicine 2010, Vol 10, No 1: 45 9 Primary hyperparathyroidism is mild disease worth treating? NJL Gittoes and MS Cooper ABSTRACT Most patients with primary hyperparathyroidism
More informationDefinition Elevated Adjusted Calcium > 2.6 mmol/l (adjusted for albumin), taken without using a cuff.
Hypercalcaemia Definition Elevated Adjusted Calcium > 2.6 mmol/l (adjusted for albumin), taken without using a cuff. Mild (usually no symptoms) 2.6 3.0 mmol/l Moderate (start to develop symptoms) 3.0 3.4
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More informationVitamin D Replacement ROCKY MOUNTAIN MEETING NOV 2013 BANFF W.COKE UNIVERSITY OF TORONTO
Vitamin D Replacement ROCKY MOUNTAIN MEETING NOV 2013 BANFF W.COKE UNIVERSITY OF TORONTO Disclosures: (Academic Mea Culpa) No financial conflicts I have no expertise re: Vitamin D. OBJECTIVES: 1) Review
More informationCalcium and Parathyroid Disorders
Calcium and Parathyroid Disorders Hussain Mahmud, MD Clinical Assistant Professor of Medicine Division of Endocrinology, Diabetes, and Metabolism University of Pittsburgh Butler Memorial Hospital November
More informationClinical Policy: Vitamin D Screening Reference Number: CP.MP.HN499
Clinical Policy: Vitamin D Screening Reference Number: CP.MP.HN499 Effective Date: 12/09 Last Review Date: 7/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationDefinition Elevated Adjusted Calcium > 2.6 mmol/l (adjusted for albumin), taken without using a cuff.
Authoriser: Fiona Davidson Page 1 of 5 Hypercalcaemia Definition Elevated Adjusted Calcium > 2.6 mmol/l (adjusted for albumin), taken without using a cuff. Mild (usually no symptoms) 2.6 3.0 mmol/l Moderate
More informationDiagnosis and management of primary hyperparathyroidism
Follow the link from the online version of this article to obtain certified continuing medical education credits Diagnosis and management of primary hyperparathyroidism Shelley Pallan, 1 Mohammed Omair
More informationBone Health in Celiac Disease. Partha S. Sinha MD, PhD October 29 th, 2017
Bone Health in Celiac Disease Partha S. Sinha MD, PhD October 29 th, 2017 No Disclosures Objectives Recognize the mechanisms by which celiac disease can affect bone health Review what diagnostic tests
More informationHypocalcemia 6/8/12. Normal value. Physiologic functions. Nephron a functional unit of kidney. Influencing factors in Calcium and Phosphate Balance
Normal value Hypocalcemia Serum calcium Total mg/dl Ionized mg/dl Cord blood 9.0 ~ 11.5 5.0 ~ 6.o New born (1 st 24 hrs) 9.0 ~ 10.6 4.3 ~ 5.1 24~ 48 hrs 7.0 ~12.0 4.0 ~4.7 Child 8.8 ~10.8 4.8 ~4.92 There
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationTABLE 1. Signs and Symptoms of Primary Hyperparathyroidism 1,2,4,5 Neurologic Inability to concentrate Confusion Depression Anxiety Fatigue Cardiovasc
CONCISE REVIEW FOR CLINICIANS NONSURGICAL MANAGEMENT OF HYPERPARATHYROIDISM Nonsurgical Management of Primary Hyperparathyroidism BRYAN FARFORD, DO; R. JOHN PRESUTTI, DO; AND THOMAS J. MORAGHAN, MD Primary
More informationShon E. Meek, M.D., Ph.D. Assistant Professor of Medicine
Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine meek.shon@mayo.edu 2016 MFMER 3561772-1 Update on Vitamin D Shon Meek MD, PhD 20 th Annual Endocrine Update January 30-Feb 3, 2017 Disclosure Relevant
More informationDiagnosis and Management of Primary Hyperparathyroidism Clinical Practice Today CME
Diagnosis and Management of Primary Hyperparathyroidism Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Identify patients with primary hyperparathyroidism
More informationOsteoporosis and Chronic Kidney Disease: Diagnosis and Treatment Recommendations
Osteoporosis and Chronic Kidney Disease: Diagnosis and Treatment Recommendations Nancy E. Lane, MD Director, Center for Musculoskeletal Health Endowed Professor of Medicine and Rheumatology University
More informationClinical biochemistry of calcium and vitamin D
Clinical biochemistry of calcium and vitamin D Dr Andrew Day Consultant in Clinical Biochemistry and Metabolic Medicine University Hospitals Bristol NHS Trust e-mail: andrew.day@uhbristol.nhs.uk A 48-year
More information"Asymptomatic" Hyperparathyroidism: Reasons for Parathyroidectomy
"Asymptomatic" Hyperparathyroidism: Reasons for Parathyroidectomy Rebecca S. Sippel, M.D. Assistant Professor Department of Surgery Section of Endocrine Surgery University of Wisconsin Primary Hyperparathyroidism
More informationVITAMIN D TESTING CLINICAL GUIDELINES. Policy Number: PDS Effective Date: January 1, Table of Contents
CLINICAL GUIDELINES VITAMIN D TESTING Policy Number: PDS - 010 Effective Date: January 1, 2013 Table of Contents Page Guidelines 1 BACKGROUND 3 CLINICAL EVIDENCE 5 U.S. FOOD AND DRUG ADMINISTRATION (FDA)
More informationSecondary hyperparathyroidism an Update on Pathophysiology and Treatment
Secondary hyperparathyroidism an Update on Pathophysiology and Treatment Klaus Olgaard Copenhagen Budapest Nephrology School August 2007 HPT IN CRF Renal mass Ca 2+ 1,25(OH) 2 D 3 CaR Hyperparathyroidism
More informationWhat is the right calcium balance?
For patients with hypoparathyroidism What is the right calcium balance? Indications and Usage1 NATPARA is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia
More informationDesign: This was a longitudinal cohort study. Setting: The study took place at a referral center.
ORIGINAL ARTICLE Endocrine Care Bone Mineral Density Evolution After Successful Parathyroidectomy in Patients With Normocalcemic Primary Hyperparathyroidism Eugénie Koumakis, Jean-Claude Souberbielle,
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More information2016 Arizona AACE Meeting: Updated Guidelines for the Management of Primary Hyperparathyroidism (PHPT)
2016 Arizona AACE Meeting: Updated Guidelines for the Management of Primary Hyperparathyroidism (PHPT) Scott M. Wilhelm, MD, FACS Associate Professor and Section Head Endocrine Surgery University Hospitals-Cleveland
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationEndocrine Regulation of Calcium and Phosphate Metabolism
Endocrine Regulation of Calcium and Phosphate Metabolism Huiping Wang ( 王会平 ), PhD Department of Physiology Rm C516, Block C, Research Building, School of Medicine Tel: 88208252 Email: wanghuiping@zju.edu.cn
More informationCa, Phos and Vitamin D Metabolism in Pre-Dialysis Patients
Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients A. WADGYMAR, MD Credit Valley Hospital, Mississauga, Ontario, Canada. June 1, 2007 1 Case: 22 y/o referred to Renal Clinic Case: A.M. 29 y/o Man
More informationAgents that Affect Bone & Mineral Homeostasis
Agents that Affect Bone & Mineral Homeostasis 1 Agents that Affect Bone & Mineral Homeostasis Calcium and phosphate are the major mineral constituents of bone. They are also two of the most important minerals
More informationVitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP
Vitamin D Vitamin functioning as hormone Todd A Fearer, MD FACP Vitamin overview Vitamins are organic compounds that are essential in small amounts for normal metabolism They are different from minerals
More informationVitamin D: Vitamin D deficiency: 7/6/2010
Vitamin D: Nancy Eyler, MD, FACP Medical Director, Diabetes & Endocrinology Community Medical Center Missoula, MT Calcium and bone metabolism: Enhances intestinal absorption of both calcium and phosphorus
More informationSensipar (cinacalcet)
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationESPEN Congress Prague 2007
ESPEN Congress Prague 2007 Key papers in the field of nutrition Dietitian Geila S Rozen Key Papers in the field of Nutrition ESPEN 2007 Prague Geila S Rozen Clinical Nutrition Dep. Rambam health campus
More informationVitamin D during pregnancy and breastfeeding
Vitamin D during pregnancy and breastfeeding Getting the right nutrients and eating well when you re pregnant or breastfeeding is important for your baby s growth and development. Vitamin D helps you to
More informationSummary Statement from a Workshop on Asymptomatic Primary Hyperparathyroidism: A Perspective for the 21st Century
Summary Statement from a Workshop on Asymptomatic Primary Hyperparathyroidism: A Perspective for the 21st Century John P. Bilezikian, John T. Potts, Jr., Ghada El-Hajj Fuleihan, Michael Kleerekoper, Robert
More information4/20/2015. The Neck xt Exploration: Intraoperative Parathyroid Hormone (IOPTH) Testing During Surgical Parathyroidectomy. Learning Objectives
The Neck xt Exploration: Intraoperative Parathyroid Hormone (IOPTH) Testing During Surgical Parathyroidectomy Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning
More informationDraft Laboratory Testing for Vitamin D Deficiency Version 4.0
Draft Laboratory Testing for Vitamin D Deficiency Version 4.0 Authors Dr Gerard Boran, Consultant Chemical Pathologist, Tallaght Hospital, Dublin 24, Ireland. Dr. Jansen Seheult, Clinical Pathology Resident,
More informationThe role of calcimimetics in chronic kidney disease
http://www.kidney-international.org & 2006 International Society of Nephrology The role of calcimimetics in chronic kidney disease A Gal-Moscovici 1,2 and SM Sprague 1 1 Division of Nephrology and Hypertension,
More informationChallenges in the Management of Primary HPTH. Zaher Ajam, MD Ghada El-Hajj Fuleihan, MD, MPH
Challenges in the Management of Primary HPTH Zaher Ajam, MD Ghada El-Hajj Fuleihan, MD, MPH Case Presentation 1 This a case of a 41-year-old gentleman who is referred to Endocrinology clinic for low BMD,
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationOSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE. Lydia Au Geriatrics Ng Teng Fong Hospital
OSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE Lydia Au Geriatrics Ng Teng Fong Hospital LET S START WITH WHAT YOU WANT TO KNOW AND DO WITH A VERT FRACTURE Vertebral fractures Most common (550K
More informationCinacalcet treatment in advanced CKD - is it justified?
Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to
More informationVitamin D: Is it a superhero??
Vitamin D: Is it a superhero?? Dr. Ashraf Abdel Basset Bakr Prof. of Pediatrics 1 2 History of vitamin D discovery Sources of vitamin D and its metabolism 13 Actions of vitamin D 4 Vitamin D deficiency
More informationMalnutrition and Role of Nutrition in BMD:CKD
Malnutrition and Role of Nutrition in BMD:CKD PNDS Continuing Nutrition Education Seminar Saturday, 30 th November 2013 Fayza Khan MSC (Foods and Nutrition) R.D President,PNDS Outline Objective Malnutrition
More informationRamzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016
Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD
More informationCKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire
Pathogenesis of Metabolic Bone Disease Stuart M. Sprague, D.O. Chief, Division of Nephrology and Hypertension Professor of Medicine NorthShore University HealthSystem University of Chicago Pritzker School
More informationHYPERCALCAEMIA 101 FOR THE INTERNIST
HYPERCALCAEMIA 101 FOR THE INTERNIST Dr Chionh Siok Bee Dept of Medicine, National University Hospital siok_bee_chionh@nuhs.edu.sg Medicine Review Course 18/09/2011 Outline of Talk Definition of hypercalcaemia
More informationVITAMIN D IN HEALTH AND DISEASE
VITAMIN D IN HEALTH AND DISEASE Margus Lember University of Tartu, Estonia ESIM, Saas Fee, January 16, 2014 l It`s most healthy to live on the southern side of a mountain l Hippokrates of Kos 460-370 BC
More informationThe Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD
The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD Jess Tower MS RD LD 3/18/19 Children s Mercy Hospital jdtower@cmh.edu 816 460 1067 Disclosures Nothing to disclose 1 How
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationVitamin D and Calcium Therapy: how much is enough
Vitamin D and Calcium Therapy: how much is enough Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco DISCLOSURE Nothing to disclose 1 RECOMMENDATIONS
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationComparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):
Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients Seyed Seifollah Beladi Mousavi 1, Arman Shahriari 2 and Fatemeh Roumi 3 * 1 Department of Nephrology,
More informationThe Endocrine Society Guidelines
Vitamin D and Calcium Therapy: how much is enough DISCLOSURE Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco Nothing to disclose RECOMMENDATIONS
More informationResearch Article Primary Hyperparathyroidism: 11-Year Experience in a Single Institute in Thailand
International Endocrinology Volume 2012, Article ID 952426, 4 pages doi:10.1155/2012/952426 Research Article Primary Hyperparathyroidism: 11-Year Experience in a Single Institute in Thailand Poramaporn
More informationPrimary Hyperparathyroidism, 2018: A Comprehensive Update
Primary Hyperparathyroidism, 2018: A Comprehensive Update John P. Bilezikian, MD, PhD(hon) Silberberg Professor of Medicine Vice-Chair for International Education and Research Chief, Division of Endocrinology,
More information